Pentwater Capital Management’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

Pentwater Capital Management’s Portfolio PSTX Stock Details PSTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-8,625,000	Closed	-$82.8M	–	139
2024 Q4	$82.8M	Buy	8,625,000 +2,650,000	+44%	+$13.8M	0.91%	24
2024 Q3	$17.1M	Hold	5,975,000	–	–	0.18%	46
2024 Q2	$17.4M	Hold	5,975,000	–	–	0.22%	44
2024 Q1	$19.1M	Hold	5,975,000	–	–	0.2%	42
2023 Q4	$20.1M	Hold	5,975,000	–	–	0.23%	52
2023 Q3	$14.2M	Hold	5,975,000	–	–	0.08%	47
2023 Q2	$10.5M	Hold	5,975,000	–	–	0.07%	57
2023 Q1	$18.4M	Hold	5,975,000	–	–	0.18%	69
2022 Q4	$31.7M	Hold	5,975,000	–	–	0.56%	37
2022 Q3	$21.1M	Buy	5,975,000 +1,007,773	+20%	+$3.33M	0.24%	54
2022 Q2	$12.8M	Hold	4,967,227	–	–	0.15%	72
2022 Q1	$22.3M	Hold	4,967,227	–	–	0.27%	54
2021 Q4	$33.8M	Hold	4,967,227	–	–	0.37%	36
2021 Q3	$36.2M	Hold	4,967,227	–	–	0.37%	44
2021 Q2	$49.8M	Hold	4,967,227	–	–	0.41%	36
2021 Q1	$47.4M	Hold	4,967,227	–	–	0.45%	37
2020 Q4	$54.5M	Buy	4,967,227 +87,737	+2%	+$925K	0.66%	27
2020 Q3	$43.3M	Buy	+4,879,490	New	+$55.5M	0.56%	33

Other funds holding PSTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Pentwater Capital Management's PSTX Position: Q1 2025 in Review

Pentwater Capital Management sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 8,625,000 shares — an estimated $82.8M sold.

Pentwater Capital Management first reported a position in PSTX in Q3 2020 and held it in 18 quarters. The position peaked at $82.8M in Q4 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.

Pentwater Capital Management reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
Pentwater Capital Management sold 8,625,000 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $82.8M.
Pentwater Capital Management first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2020 and held it in 18 quarters.
Pentwater Capital Management's Poseida Therapeutics, Inc. Common Stock position peaked at $82.8M in Q4 2024.
1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Pentwater Capital Management's 13F filing for Q1 2025, filed 15 May 2025.